• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by REGENXBIO Inc.

    4/14/26 5:05:04 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGNX alert in real time by email
    DEFA14A 1 rgnx-2026-proxy-addition.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒ Filed by a party other than the Registrant ☐

    Check the appropriate box:
    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material Pursuant to §240.14a-12

    REGENXBIO Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒ No fee required

    ☐ Fee paid previously with preliminary materials

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rule 14a-6(i)(1) and 0-11


    img228908952_0.jpg

    Your Vote Counts! REGENXBIO INC. 2026 Annual Meeting Vote by May 28, 2026 11:59 PM Eastern Time REGENXBIO® REGENXBIO INC 9804 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850 V92514-P51733 You invested in REGENXBIO INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 29, 2026. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 15, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. P For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Vote in Person at the Meeting* Point your camera here and May 29, 2026 vote without entering a 9:00 a.m. Eastern Time control number 9804 Medical Center Drive Rockville, Maryland 20850 *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

     


    img228908952_1.jpg

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is only an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1. Election of three Class Il Directors Nominees: 01) Jean Bennett, M.D., Ph.D For All 02) A.N. "Jerry" Karabelas, Ph.D. 03) Daniel Tassé 2. To ratify the appointment of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the Company's independent registered public accounting firm for the year ending December 31, 2026. v For 3. Advisory vote on the compensation paid to the Company's executive employees. ~ For 4. To approve a stock option exchange for our non-executive employees. For 5. To approve a stock option exchange for our executive employees. For NOTE: Other business may be considered as may properly come before the meeting and any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings". V92515-P51733


    Get the next $RGNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RGNX

    DatePrice TargetRatingAnalyst
    1/28/2026$37.00Overweight
    Barclays
    2/11/2025$38.00 → $14.00Buy → Neutral
    Goldman
    2/7/2025$27.00Outperform
    Raymond James
    11/15/2024$22.00Overweight
    Morgan Stanley
    10/10/2024$18.00Outperform
    Raymond James
    6/7/2024$38.00Buy
    Goldman
    3/11/2024$36.00Buy
    H.C. Wainwright
    3/8/2024$20.00 → $35.00Sector Perform → Outperform
    RBC Capital Mkts
    More analyst ratings

    $RGNX
    SEC Filings

    View All

    SEC Form SC TO-I filed by REGENXBIO Inc.

    SC TO-I - REGENXBIO Inc. (0001590877) (Subject)

    6/3/26 8:11:18 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

    8-K - REGENXBIO Inc. (0001590877) (Filer)

    6/3/26 7:30:16 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by REGENXBIO Inc.

    10-Q - REGENXBIO Inc. (0001590877) (Filer)

    5/14/26 7:30:43 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    REGENXBIO to Participate in Upcoming Investor Conferences

    ROCKVILLE, Md., May 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced it will participate in the following investor conferences:2026 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 20 at 9:30am ET Location: New York, NYStifel 2026 Virtual Ophthalmology Forum Fireside Chat: Tuesday, May 26 at 9:30am ET Location: VirtualLive webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. Archived replays of the webcasts will be available for approximately 30 days following the events.ABOUT REGENXBIO Inc. REGENXBIO is a biotechnology company on a mission to improve lives through the curative poten

    5/18/26 4:05:00 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

    Company announced positive topline results from pivotal Phase III AFFINITY DUCHENNE® study of RGX-202Primary endpoint achieved with high statistical significanceStatistically significant correlation between RGX-202 microdystrophin expression and functional improvement (NSAA, n=9), supporting validity of surrogate endpoint Surabgene lomparvovec (sura-vec, ABBV-RGX-314) on track toward key catalysts Sites activated in pivotal Phase IIb/III study for diabetic retinopathy; first patient dosed expected Q2 2026Subretinal wet AMD topline pivotal data expected in Q4 2026Clinical hold lifted for RGX-121Webcast today at 8:00 a.m. ET to discuss RGX-202 topline pivotal data and Q1 2026 earnings ROCKVILL

    5/14/26 7:10:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202

    Achieved primary endpoint with high statistical significance; 93% of patients achieved microdystrophin expression above 10% (p<0.0001)Statistically significant correlation between RGX-202 microdystrophin expression and functional improvement (NSAA n=9), supporting validity of surrogate endpoint Well-tolerated, differentiated safety profileCompany preparing for potential accelerated approval in 2027Webcast to be held at 8:00 a.m. ET todayROCKVILLE, Md., May 14, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) announced positive topline and interim functional data from the pivotal Phase III portion of the Phase I/II/III AFFINITY DUCHENNE® trial of RGX-202, a potential best-in-class gene thera

    5/14/26 7:00:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on REGENXBIO with a new price target

    Barclays resumed coverage of REGENXBIO with a rating of Overweight and set a new price target of $37.00

    1/28/26 7:18:39 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO downgraded by Goldman with a new price target

    Goldman downgraded REGENXBIO from Buy to Neutral and set a new price target of $14.00 from $38.00 previously

    2/11/25 7:12:20 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James resumed coverage on REGENXBIO with a new price target

    Raymond James resumed coverage of REGENXBIO with a rating of Outperform and set a new price target of $27.00

    2/7/25 8:29:59 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tasse Daniel was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)

    4 - REGENXBIO Inc. (0001590877) (Issuer)

    6/2/26 5:21:14 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Stump David C was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)

    4 - REGENXBIO Inc. (0001590877) (Issuer)

    6/2/26 5:20:59 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Zachary Jennifer was granted 9,807 shares, increasing direct ownership by 44% to 31,871 units (SEC Form 4)

    4 - REGENXBIO Inc. (0001590877) (Issuer)

    6/2/26 5:20:47 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Financials

    Live finance-specific insights

    View All

    REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

    Company announced positive topline results from pivotal Phase III AFFINITY DUCHENNE® study of RGX-202Primary endpoint achieved with high statistical significanceStatistically significant correlation between RGX-202 microdystrophin expression and functional improvement (NSAA, n=9), supporting validity of surrogate endpoint Surabgene lomparvovec (sura-vec, ABBV-RGX-314) on track toward key catalysts Sites activated in pivotal Phase IIb/III study for diabetic retinopathy; first patient dosed expected Q2 2026Subretinal wet AMD topline pivotal data expected in Q4 2026Clinical hold lifted for RGX-121Webcast today at 8:00 a.m. ET to discuss RGX-202 topline pivotal data and Q1 2026 earnings ROCKVILL

    5/14/26 7:10:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected early Q2 2026Robust patient enrollment continues in confirmatory trialSurabgene lomparvovec (sura-vec, ABBV-RGX-314) subretinal wet AMD topline pivotal data expected in Q4 2026; first patient dosed in pivotal Phase IIb/III trial in diabetic retinopathy expected in Q2 2026Company to engage FDA on potential path forward for RGX-121Conference call today at 8:00 a.m. ETROCKVILLE, Md., March 5, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today reported financial results and operational highlights f

    3/5/26 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    ROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology comp

    2/25/26 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Leadership Updates

    Live Leadership Updates

    View All

    Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

    12/6/24 6:29:00 PM ET
    $AMTM
    $APO
    $CMA
    Real Estate
    Investment Managers
    Finance
    Major Banks

    REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

    Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programsVit Vasista steps down following more than 15 years at the CompanyROCKVILLE, Md., Sept. 17, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Mitchell Chan has been appointed as Executive Vice President and Chief Financial Officer, effective today. A veteran finance executive and operating partner in the biotechnology industry, Mr. Chan has held key roles in raising capital, business development transactions and operations for nearly 20 years.  "We are excited to welcome Mitchell at this exciting time for REGENXBIO," said Curran Simpson, President and

    9/17/24 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Announces Leadership Transition

    Curran Simpson, Chief Operating Officer, Appointed as President and CEOCo-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md., June 12, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as RE

    6/12/24 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

    SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    11/14/24 9:00:57 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

    SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    11/12/24 4:47:45 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

    SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    11/4/24 1:49:56 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care